Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
2.32 USD | +3.57% | +3.57% | -35.73% |
Mar. 25 | Finch Therapeutics Group, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023 | CI |
Mar. 12 | Top Premarket Decliners | MT |
Financials (USD)
Sales 2022 | 861K | Sales 2023 | 107K | Capitalization | 5.8M |
---|---|---|---|---|---|
Net income 2022 | -115M | Net income 2023 | -74M | EV / Sales 2022 | 5.01 x |
Net cash position 2022 | 18.68M | Net Debt 2023 | 5M | EV / Sales 2023 | 101 x |
P/E ratio 2022 |
-0.2
x | P/E ratio 2023 |
-0.08
x | Employees | 1 |
Yield 2022 * |
-
| Yield 2023 |
-
| Free-Float | 46.52% |
1 day | +3.57% | ||
1 week | +3.57% | ||
Current month | -10.77% | ||
1 month | -19.84% | ||
3 months | -20.00% | ||
6 months | -37.97% | ||
Current year | -35.73% |
Managers | Title | Age | Since |
---|---|---|---|
Matthew Blischak
CEO | Chief Executive Officer | - | 23-05-15 |
Lance Thibault
DFI | Director of Finance/CFO | 58 | 23-05-15 |
Sonia Timberlake
CTO | Chief Tech/Sci/R&D Officer | - | - |
Members of the board | Title | Age | Since |
---|---|---|---|
Susan Graf
CHM | Chairman | 52 | 21-04-22 |
Jeffery Smisek
BRD | Director/Board Member | 69 | 17-08-31 |
Chris W. Shumway
BRD | Director/Board Member | 58 | 20-08-31 |
Date | Price | Change | Volume |
---|---|---|---|
24-04-26 | 2.32 | +3.57% | 38,235 |
24-04-25 | 2.24 | -2.61% | 41,721 |
24-04-24 | 2.3 | -17.53% | 118,273 |
24-04-23 | 2.789 | +20.73% | 693,546 |
24-04-22 | 2.31 | +3.12% | 25,094 |
Delayed Quote Nasdaq, April 26, 2024 at 04:30 pm EDT
More quotes1st Jan change | Capi. | |
---|---|---|
-35.73% | 3.73M | |
+1.51% | 42.75B | |
+49.22% | 41.61B | |
+8.57% | 41.34B | |
-12.36% | 26.59B | |
+8.92% | 25.49B | |
-25.13% | 18.12B | |
+29.17% | 12.24B | |
-3.12% | 11.76B | |
+6.35% | 11B |
- Stock Market
- Equities
- FNCH Stock